SCHEMBL25157286

SCHEMBL25157286

FC1(F)CCC(CNc2ncc3c(-c4ccc5nccnc5c4)c[nH]c3n2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.40
▸ BRD4 O60885 2/20 0.40
▸ CLK2 P49760 2/20 0.38
▸ CLK3 P49761 2/20 0.38
▸ ROCK2 O75116 2/20 0.38
▸ CDC7 O00311 1/20 0.38
▸ CCNB2 O95067 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ RET P07949 1/20 0.38
▸ CCNB1 P14635 1/20 0.38
▸ PRKACA P17612 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ CCNB3 Q8WWL7 1/20 0.38
▸ HIPK2 Q9H2X6 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.35
▸ IRAK1 P51617 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30346905 1.00 DYRK1A (0.40) DYRK1ABRD4CLK2CLK3ROCK2
SCHEMBL30407829 0.90 DYRK1A (0.49) DYRK1ABRD4CLK2CLK3ROCK2
SCHEMBL25519871 0.90 DYRK1A (0.49) DYRK1ABRD4CLK2CLK3ROCK2
SCHEMBL25157439 0.86 TDO2 (0.45) DYRK1ABRD4CLK2CLK3ROCK2
SCHEMBL30346467 0.85 BRD4 (0.41) DYRK1ABRD4CLK2CLK3CDC7
SCHEMBL25519916 0.85 BRD4 (0.41) DYRK1ABRD4CLK2CLK3CDC7
SCHEMBL30406857 0.85 DYRK1A (0.49) DYRK1ABRD4CLK2CLK3ROCK2
SCHEMBL25519924 0.85 DYRK1A (0.49) DYRK1ABRD4CLK2CLK3ROCK2
SCHEMBL30348056 0.84 BRD4 (0.38) DYRK1ABRD4CLK2CLK3USP30
SCHEMBL25518089 0.84 BRD4 (0.38) DYRK1ABRD4CLK2CLK3USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885BRD4 1417/4885CLK2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback